Our compelling findings, derived directly from a comprehensive, multi-signature pathway signaling analysis of thousands of CRC tumors, have suggested a mechanism and means to subvert AR (or intrinsic resistance) in the highly drug-resistant CSC, by inhibiting a common SRC signaling node. This evidence concerns the gene AR and colorectal carcinoma.